Ascendis Pharma

Company snapshot

Ascendis Pharma Bone is a pharma organization headquartered in EU. Primary therapeutic focus areas include Hypoparathyroidism (HP) in Adults, Chronic hypoparathyroidism. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (1), phase 3 (1).

• 2 active pipeline program(s) linked via ClinicalTrials.gov.
• 12 US patent(s) indexed to this assignee profile.
• 2 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Ascendis Pharma. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Ascendis Pharma.

1. Jun 8, 2026 Clinical update

   ASND0035 — Phase 3

2. May 26, 2026 Clinical update

   TransCon PTH — Phase 2

3. Mar 13, 2025 Patent grant

   TRAITEMENT PAR PTH D'UNE MALADIE RÉNALE CHRONIQUE

4. May 10, 2024 Patent grant

   RÉGIME DE TRAITEMENT À BASE DE PTH COMPRENANT DEUX COMPOSÉS PTH

5. Oct 12, 2023 Patent grant

   Dosage Regimen for a Controlled-Release PTH Compound

View all clinical trial activity →

• What is Ascendis Pharma?

  Ascendis Pharma Bone is a pharma organization headquartered in EU. Primary therapeutic focus areas include Hypoparathyroidism (HP) in Adults, Chronic hypoparathyroidism. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from publ

• Is Ascendis Pharma publicly traded?

  Ascendis Pharma appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Ascendis Pharma develop or market?

  We link 3 drug profile(s) where Ascendis Pharma is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/ascendis-pharma-bone-diseases-a-s#company-drugs.

• What are the latest developments for Ascendis Pharma?

  In the last 12 months our linked public records show 2 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Ascendis Pharma focus on?

  Ascendis Pharma focuses on Hypoparathyroidism (HP) in Adults, Chronic hypoparathyroidism based on our analysis of their pipeline programs and drug development activities.